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External validationa b s t r a c t
Purpose: To develop and externally validate a predictive model for pathologic complete response (pCR)
for locally advanced rectal cancer (LARC) based on clinical features and early sequential 18F-FDG PETCT
imaging.
Materials and methods: Prospective data (i.a. THUNDER trial) were used to train (N = 112, MAASTRO
Clinic) and validate (N = 78, Università Cattolica del S. Cuore) the model for pCR (ypT0N0). All patients
received long-course chemoradiotherapy (CRT) and surgery. Clinical parameters were age, gender, clini-
cal tumour (cT) stage and clinical nodal (cN) stage. PET parameters were SUVmax, SUVmean, metabolic
tumour volume (MTV) and maximal tumour diameter, for which response indices between pre-treat-
ment and intermediate scan were calculated. Using multivariate logistic regression, three probability
groups for pCR were deﬁned.
Results: The pCR rates were 21.4% (training) and 23.1% (validation). The selected predictive features for
pCR were cT-stage, cN-stage, response index of SUVmean and maximal tumour diameter during treatment.
The models’ performances (AUC) were 0.78 (training) and 0.70 (validation). The high probability group
for pCR resulted in 100% correct predictions for training and 67% for validation. The model is available
on the website www.predictcancer.org.
Conclusions: The developed predictive model for pCR is accurate and externally validated. This model
may assist in treatment decisions during CRT to select complete responders for a wait-and-see policy,
good responders for extra RT boost and bad responders for additional chemotherapy.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 215–222
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).Early prediction of pathologic complete response (pCR) for
locally advanced rectal cancer (LARC) patients is valuable because
it allows for individualized treatment reorientation [15,28]. The
standard treatment for LARC patients is preoperative chemoradio-
therapy (CRT) followed by surgery. The neo-adjuvant treatment,
intended to control pelvic disease and improve the chance of
sphincter preservation, results in a pathological complete response
(pCR) in 15–30% of the patients [9,21]. For these complete respond-
ers a wait-and-see policy after CRT is a possibility in order to
reduce treatment-related morbidity and mortality, for whichexcellent results are reported [20]. This decision requires however
very accurate predictions and assessment of complete response.
Other treatment options under consideration are a radiotherapy
boost after CRT for good responding patients to achieve more pCRs
[8] and additional chemotherapy administration after CRT for the
worst responding patients [3]. Both of these options require an
early assessment of response even during CRT. Currently, the lead-
ing candidate predictive marker for histopathological response
prediction in LARC is 18F-ﬂuorodeoxyglucose (FDG) positron emis-
sion tomography (PET) imaging. A meta-analysis from 2012 con-
ﬁrmed the added value of PET imaging, especially for
intermediate PET imaging (during CRT) [31]. However, most stud-
ies evaluated pre-CRT versus post-CRT PET imaging. Besides that
early prediction is preferred for treatment reorientation, later pre-
216 Nomogram for response using PET during treatment in rectal cancerdictions may also be affected by CRT-induced inﬂammatory tissue,
which presents tumour equivalent signal on FDG-PET scans [26].
This recognition resulted in more early response assessment stud-
ies in the last few years (Table 1). The limitations of these studies
were their small sample sizes (N = 20–42), the main focus on good
versus bad responders (not pCR), the univariate setting in which
analyses were performed and the lack of validation. To increase
the clinical applicability of these decision making tools, they need
to be based on more evidence (i.e. larger number of patients and
external validation), be trained on several data sources [29] and
they require focus on outcomes that are more relevant in terms
of decisions, like pCR for a possible wait-and-see policy. We
hypothesize that models with these requirements are the most
suitable for decision making in clinical practice. The aim of this
study is therefore to develop an externally validated multivariate
predictive model for pCR combining clinical, pre-treatment and
intermediate FDG-PETCT imaging parameters based on a prospec-
tive study. After development of a nomogram and the evaluation of
its accuracy, risk group deﬁnition based on these predictions may
provide decision support to clinicians for LARC patients (Fig. 1).
Materials and methods
Study population
All data were prospectively collected (with written informed
consent) between January 2007 and March 2012 within two insti-
tutes: MAASTRO Clinic (GROW, MUMC, Maastricht, The Nether-
lands) and Università Cattolica del S. Cuore (Rome, Italy). The
following prospective observational studies were involved: a study
(2007–2009) involving 47 patients from Maastricht [12,14], a pilot
study (2007–2009) with 19 patients from Rome and a multicentre
study (2009–2012) involving one protocol for both institutes
(MAASTRO: 65 patients, Rome: 59 patients) with acronym THUN-
DER (THeragnostic Utilities for Neoplastic DisEases of the Rectum,
NCT00969657). All patients from Maastricht were pooled and used
to train a prediction model for pCR (N = 112). The pooled datasets
from Rome were used for external validation of the model (N = 78).
The study inclusion criteria were: histological proven rectal cancer
(primary tumours), UICC stage I–III, no recurrences, only concur-
rent chemoradiotherapy treatment, minimal age of 18 years, and
no previous radiotherapy to the pelvis. The available clinical vari-Fig. 1. Schematic overview of prediction model development (top) and the proposed app
a control arm (bottom).ables used as candidate prognostic and predictive factors were
age, gender, clinical tumour (cT) and nodal (cN) stage. The criteria
followed to consider tumour nodal involvement at MRI were
related to border contour (sharply demarcated or irregular border)
and signal intensity characteristics (homogeneous or inhomoge-
neous) or size >8 mm [2,7]. All patients from Maastricht were trea-
ted preoperatively with radiotherapy (28 fractions of 1.8 Gy, 5
fractions/week) and concomitant chemotherapy (capecitabine,
825 mg/m2, twice daily), followed by a total mesorectal excision
6–8 weeks after the end of CRT. A minority of the thunder patients
(N = 11) with a clinical complete response (assessed using post-
CRT MRI and endoscopy) were enrolled in a parallel study where
a surgical wait-and-see policy was applied [20]. Some patients
from Rome were also treated with 50.4 Gy schedule, but 78.2% of
the patients were treated with 25  1.8 Gy schedule and a RT boost
of 10 Gy. The majority of the Rome patients (N = 62) received a
combination of capecitabine (1300 mg/m2 daily) and oxaliplatin
(60 mg/m2 once a week for 5 weeks with 55.0 Gy RT or 130 mg/m2
at 3 time points with 50.4 Gy RT), and the others capecitabine only
(1650 mg/m2 daily with 50.4 Gy RT or 1300 mg/m2 daily with
55 Gy RT, N = 14) or raltitrexed (3 mg/m2 at 3 time points, N = 2).PETCT imaging
All patients underwent a pre-CRT PET scan (one week before
the start of CRT) and an intermediate PET scan (two weeks after the
start of CRT). All Maastricht PET-CT scans were performed by use of
a dedicated Siemens Biograph 40 TruePoint PET-CT scanner (Sie-
mens Medical, Erlangen, Germany). Rome scans were performed
with a 3D GEMINI GXL PET-CT scanner with 16 slice CT (Philips
Healthcare, Cleveland, OH). The PET acquisition settings were
reported before and were calibrated for both institutes [14]. PET-
based semi-automatic tumour contoursweremade by one observer
using a dedicated software (TrueD, SiemensMedical, Erlangen, Ger-
many). Contours were deﬁned by a threshold for the standardized
uptake-value (SUV) based on the tumour-to-background signal
ratio, with the gluteus muscle as reference background [6,23].
From the resulting tumour contour, maximal tumour diameter
(MaxDiam), metabolic tumour volume (MTV), and maximal and
mean SUV values within the MTV were calculated. The same
variables were scored for the intermediate CRT PET-CT scan andlication of the model in clinical practice after it has been tested in a clinical trial with
Table 1
All studies for response prediction in locally advanced rectal cancer using early sequential PET imaging.
Study Year Accrual time N RT dose (Gy) Chemo 2nd PET (days) Surg (weeks) Outcome PA Predictors AUC

















Leibold [17] 2011 2001–2005 27 50.4 5-FU 8–14 5–8 Resp 95%a VRS NR
Lambrecht [16] 2010 2005.5–2009.8 22 50.4 5-FU 14–16 6–8 pCR TNM DSUVmax NR
Janssen [12]b 2009 2007.4–2009.3 30 50.4 Cap 8 + 15c 6–8 Resp TRG DSUVmax
DSUVmean
0.87
Guerra [11] 2009 2006.5–2009.3 28 50.4 5-FU 21 12 Resp TRG SUVimean 0.83
Rosenberg [25] 2008 2006.3–2007.1 30 45 5-FU 14 5 Resp TRGd Nonee 0.70









2nd PET: time between start of chemoradiotherapy and the intermediate PET-scan; 5-FU: ﬂuorouracil; Cap: capecitabine; DSUV: (relative) difference between pretreatment
and intermediate standard uptake value of the PET contour; LFA: levofolinic acid; N: number of patients in study; NR: not reported; Oxa: oxaliplatin; PA: pathology; pCR:
pathologic complete response; Ral: raltitrexed; Resp: tumour response; RT: radiotherapy; Surg: time between end of chemoradiotherapy and surgery; SUVi: intermediate
standard uptake value of the PET contour; TRG: tumour regression grade; VRS: visual response score; UFT: tegafur–uracil.
a Pathologic response >95%.
b The separate validation study is not reported [14].
c Results reported for day 15 (optimal time point in this study).
d According to Becker standard, other studies used Mandard standard.
e Trend for DSUVmean (p = .085).
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relative difference between the value of the intermediate scan and
pre-CRT scan and deﬁned as (Xpre  Xintermediate)/Xpre * 100%. SUV
measures were corrected for blood glucose level [13].Pathological assessment
Pathological complete response was deﬁned as ypT0N0,
extracted from the pathologic reports of surgical specimens. All
other cases (ypT+ and/or ypN+) were considered non-responders.
The specimens were not re-evaluated centrally but the pathology
protocols were very similar between institutes (3–5 mm slices of
rectum tumour, intensiﬁed evaluation on several blocks of tissue
at the tumour site, evaluation on 2–3 sublevels when no tumour
tissue was found in initial block). For the 11 wait-and-see patients,
a pCR was assigned if the patient was locally recurrence free after
12 months of follow-up, a time point motivated by the extremely
low recurrence rate in the wait-and-see study [20].Statistical analysis
All statistical analyses were implemented and performed in
MATLAB (version 7.1, MathWorks Inc., Natick, MA). Any missing
values (Maastricht: 1.1%, Rome: 1.9%) in the datasets were substi-
tuted using the Expectation–Maximization method [18]. Datasets
were pooled per institute on an individual patient level. Wilcoxon
rank-sum tests were performed to test for association between a
single variable and pCR. In the multivariate setting, logistic regres-
sion was applied to classify complete responders and non-respond-
ers, using the signiﬁcant predictors from the univariate analysis as
inputs. In the case of two very highly correlated input variables,
only one was selected (using Spearman’s correlation matrix,
p < .05). The model’s accuracy was evaluated with the area under
the curve (AUC) of the receiver operating characteristic (ROC)
curve [24]. The maximum value of the AUC is 1.0, indicating a per-
fect prediction model while a value of 0.5 indicates a random
chance of correct prediction. Predictors were only selected if their
addition resulted in a sufﬁcient AUC change (>.01). For the ﬁnalaccuracy assessment, a bootstrapping scheme was applied (sam-
pling with replacement, N = 1000), resulting in 95% conﬁdence
intervals for AUC. A nomogram was generated to represent a visu-
alization of the ﬁnal predictive model in which three risk groups
were deﬁned by applying two thresholds for the estimated proba-
bility for pCR. To deﬁne the low probability group for pCR, ﬁrst the
(weighted) average rate of non-responders (TRG3–4, tumour
regression grade) was calculated from literature and thereafter a
threshold was selected that resulted in this percentage of non-
responders [1,5,10,11,14,17]. The threshold for the high estimated
probability of pCR was calculated using decision curve analysis
[30]. This method optimizes the threshold by calculating the net
beneﬁt of applying such a model and comparing it to the situations
in which none or all patients are treated with a wait-and-see pol-
icy. These two thresholds deﬁne the three probability groups for
pCR (high, mid, low), which correspond respectively to complete,
good and bad responders with respect to pCR.Results
Dataset characterization
Pooling the clinical and PETCT imaging data per institute
resulted in similar cohort characteristics (Table 2). The validation
dataset from Rome had in general: less males (64.1% vs 74.1%,
p = .187), higher clinical tumour stages (cT4: 30.8% vs 8.0%,
p < .001), and more nodal involvement (94.9% vs 86.6%, p = .10).
Almost all Maastricht patients received 50.4 Gy of RT (95.5%) while
the majority of the Rome patients received 55.0 Gy (78.2%). There
was also a small but non-signiﬁcant difference in the number of
pathologic complete responders (23.1% vs 21.4%, p = .927). The
average time from last RT fraction to surgery was equal
(73.6 ± 18.8 vs 72.9 ± 13.2 days, mean ± SD). Despite harmoniza-
tion of the PET protocols in the THUNDER study, the time between
the PET scans was on average lower for the Maastricht dataset
(21.9 ± 2.5 vs 28.5 ± 10.5 days). Also the time between tracer injec-
tion and PET acquisition was lower for the intermediate PET scan in
Maastricht (69.5 ± 15.2 vs 81.9 ± 23.0 min).
Table 2
Patient characteristics of the training data set (Maastricht) and the validation data set (Rome).
Maastricht Rome
N [%] N [%]
Clinical Sex
Female 29 [25.9] 28 [35.9]





2 17 [15.2] 5 [6.4]
3 86 [76.8] 49 [62.8]
4 9 [8.0] 24 [30.8]
Clinical nodal stage
0 15 [13.4] 4 [5.1]
+ 97 [86.6] 74 [94.9]
PET imaging Time between PET scans (days)
Mean 21.9 28.5
Standard deviation ±2.5 ±10.5
Time 1st PET injection to acquisition (minutes)
Mean 82.6 80.2
Standard deviation ±18.1 ±21.3
Time 2nd PET injection to acquisition (minutes)
Mean 69.2 81.9
Standard deviation ±15.2 ±23.0
Treatment Total radiotherapy dose (Gy)
<50.4 5 [4.5] 2 [2.6]
50.4 107 [95.5] 15 [19.2]
55.0 0 [0.0] 61 [78.2]
Time last RT fraction to surgery (days)
Mean 73.6 72.9
Standard deviation ±18.8 ±13.2
Outcome Pathologic complete response
Yes 24 [21.4] 18 [23.1]
No 88 [78.6] 60 [76.9]
218 Nomogram for response using PET during treatment in rectal cancerPredictor selection
Univariate analyses (Table 3) showed that age, pre-treatment
SUV measures, intermediate SUVmean, and response index for max-
imal diameter have no signiﬁcant predictive value for pCR (a = .05).
Negatively correlated signiﬁcant predictors (i.e. increasing value
results in lower pCR rate) were cT-stage, cN-stage, pre-treatment
and intermediate MTV and maximal diameter, and intermediate
SUVmax. Positively correlated signiﬁcant predictors (i.e. increasing
value results in higher pCR rate) were the response indexes forTable 3
Prediction results. For each variable, the distributions are compared between training
Multivariate analysis including feature selection are included.
Univariate Multivariate
p pCR " OR [95% C
Gender .048⁄ Female 0.65 [0.19–
Age .523 –
cT-stage .002⁄ ; 0.20 [0.05–
cN-stage .001⁄ ; 0.21 [0.04–
SUVmean0 .747 –
SUVmax0 .617 –
MTV0 .002⁄ ; 1.08 [1.00–
MaxDiam0 .004⁄ ; 0.90 [0.42–
SUVmean15 .067 –
SUVmax15 .030⁄ ; 0.96 [0.83–
MTV15 .000⁄ ; 0.82 [0.67–
MaxDiam15 .005⁄ ; 0.95 [0.58–
RI_SUVmean .022⁄ " 1.01 [0.90–
RI_SUVmax .030⁄ " 1.01 [0.91–
RI_MTV .017⁄ " 0.99 [0.96–
RI_MaxDiam .544 –
Signiﬁcant p-values are indicated by an asterisk (⁄).SUVmean, SUVmax and MTV. Female gender was also found to be sig-
niﬁcantly associated with high pCR rate.
In multivariate logistic modelling only cT-stage was found sig-
niﬁcant in the total group of input predictors (p = .027⁄). However,
highly correlated input variables increase p-values in a multivari-
ate setting (Fig. 2). The following decisions were made based on
the analyses to select the ﬁnal set of predictors:
 Gender was excluded: non-signiﬁcant p-value and no other cor-
relations with inputsand validation dataset and a univariate analysis is performed (training set only).
Predictor selection
I] p OR [95% CI] p
2.23] .495
0.83] .027⁄ 0.19 [0.06–0.64] .007⁄





1.56] .849 0.74 [0.53–1.03] .078









































































































Fig. 2. Spearman correlation matrix to identify signiﬁcant (boxed + inner circle) correlations between model input variables.
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(p = .056)
 The MTVmeasures were excluded: many outliers were detected
(pre-treatment: N = 11 with MTV differences up to 4 times the
average volume, intermediate: N = 12 with MTV differences
up to 10 times the average volume). These measures also did
not have an added predictive value to the ﬁnal selection.
 RI of SUVmean was included at the expense of RI of SUVmax: lit-
erature reported sufﬁcient evidence for both of them (Table 1).
However, these measures are highly correlated (Fig. 2). Univari-
ately, RI of SUVmean had highest discriminative ability (p = .022⁄
vs p = .030⁄) and was therefore selected.
 From the other predictors, pre-treatment and intermediate
maximal diameter and intermediate SUVmax, only intermediate
maximal diameter was selected because it showed an AUC
increase >0.02 when added to the ﬁnal set (and signiﬁcance
a < 0.1).
Hence, the ﬁnal selected predictors in the multivariate model
were cT-stage (p = .007⁄), cN-stage (p = .032⁄), intermediate maxi-
mal diameter (p = .078) and RI of SUVmean (p = .025⁄).Validation of the nomogram
The multivariate model with the four selected predictors to
estimate the probability of a pCR was visually represented by a
nomogram (Fig. 3A). Bootstrapped AUCs were 0.78 (95% CI: 0.65–
0.89) for the training dataset and 0.70 (95% CI: 0.55–0.84) for the
validation dataset. With the aim of estimating three probability
groups for pCR, two probability thresholds were deﬁned to sepa-
rate these groups. The 12.8% threshold (<12.8% low probabilityon pCR, >12.8% medium probability of pCR) was deﬁned based
on literature in which on average 49.2% of the patients are non-
responders (weighted for number of patients). The other threshold
was calculated at 53% based on decision curve analysis where the
optimal net beneﬁt of applying a wait-and-see policy was maxi-
mized (Fig. S1). These three probability groups (low, medium, high)
resulted in signiﬁcantly increasing pCR rates (training data: respec-
tively 7.3%, 21.3%, 100% pCR; validation data: 13.0%, 30.8% and
66.7% pCR). The highest probability groups contained 8.9% (train-
ing) and 7.7% (validation) of the total number of patients, while
the lowest probability groups contained respectively 49.1% and
59.0% (Fig. 3B).
Discussion
In this study a multivariate nomogram with clinical parameters
and early sequential PETCT imaging markers predicting pCR in
LARC was developed based on a large prospective study and vali-
dated prospectively within another institute. Good performances
were measured for both training and validation dataset. After risk
group identiﬁcation a subgroup of just below 10% of the patients
with high estimated probability for complete response was
identiﬁed.Model predictors
The selected predictive factors for pCR were cT-stage, cN-stage,
DSUVmean and intermediate maximal tumour diameter. A recent
large analysis of 3105 patients found that cT-stage was predictive
for pCR (p < .0001) but that cN-stage shows only a trend (p = .10)
[21]. This study contained however also old cases where CT was
AB
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Fig. 3. (A) Nomogram of pathologic complete response based on the multivariate analysis. Three probability groups are deﬁned and pCR rates of those groups are plotted. (B)
Actual pCR rates in the training and validation set plotted for three probability groups from the model, which are deﬁned by low: p 6 12.8%, medium: 12.8% < p < 53%, high:
pP 53%. Relative number of patients in the group (%) is shown above the bars. The model is available on www.predictcancer.org.
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ated both cT-stage (p < .001) and cN-stage (p < .001) with pCR [29].
The same study also found that pre-treatment (metabolic) tumour
size was predictive (p = .003), but others show that only changes in
metabolic volume in the pre-post treatment setting were signiﬁ-
cant for pCR and not the intermediate case (p = .010) [27]. In the
presented study’s univariate analysis, it is clear that tumour size
is important for pCR. The change in SUVmean at the intermediate
time point was found predictive in earlier studies for responders
versus non-responders [1,5,14], but SUVmax is stronger when pre-
dictions for pCR changes are made [10,16]. In our study the
response index of SUVmean was a stronger predictor than the RI
of SUVmax. These two measures are also highly correlated, espe-
cially since our PET contouring was semi-automatic and calibrated
for both institutes, resulting in less variation in SUVmean due to
contouring [4].
A variable selection scheme was chosen based on univariate
analysis, correlation between input variables and contribution to
multivariate prediction performance. Other strategies such as
penalized feature selection are also common when dealing with
highly correlated variables, but in general this results in interpret-
ability issues for the (shrunken) coefﬁcients [19].Model performance
The performance of the nomogram measured by AUC of 0.78
(95% CI: 0.65–0.89) for the training dataset and 0.70 (95% CI:0.55–0.84) for the validation dataset are lower than the ones
reported by single PET parameters in literature (0.70 [25], 0.83
[11], 0.87 [14]). However, these studies predict response (TRG1–
2) instead of pCR. Response prediction is in practice more accurate
because the number of events for good response (45–55%) is much
higher than that of pCR (15–30%). Identifying the complete
responders in an early phase is useful to avoid additional treat-
ments and related toxicity for these patients. Another possible rea-
son for a lower overall performance can be the noisy pathology
outcome (noncentralized), but this is compensated by the high
number of patients. The current studies reported in literature with
low number of samples are sensitive to positive (or negative) ﬁnd-
ings by mere chance, and therefore it is reasoned that this large
study’s performance is expected to reﬂect reality better.
When stratifying the patients in three risk groups, the perfor-
mance is acceptable: 100% accuracy for high probability for pCR
group for the training dataset (N = 10) and 67% for the validation
dataset (N = 6). The two misclassiﬁed patients in the validation
set have TRG2, ypT1N0 or ypT2N0 status and a clinical response
on the PETCT scan two months after the end of CRT, thus they
are considered as good responders. The model is very conservative
in selecting patients with high probability for pCR because the aim
is to keep the number of false positives as low as possible to avoid
undertreatment in a wait-and-see policy. This means that patients
that present a pCR eventually still end up in the predicted good and
bad responder group as indicated in Supplementary Table S2.
These patients might get overtreatment in case extra RT is
R.G.P.M. van Stiphout et al. / Radiotherapy and Oncology 113 (2014) 215–222 221administered for good responders, but we believe the increased
pCR rate beneﬁt for this group outweighs the possible mild
complications.
The difference in performance between training and valida-
tion dataset is likely to be based on differently distributed data
with respect to the predictors. The validation set has lower
model estimates for the probabilities of pCR due to higher pre-
treatment cT-stages (p = .007), and signiﬁcantly lower RIs of
SUVmean (p < .001). The latter difference may be explained by
the higher times between tracer injection and the intermediate
PET acquisition in the validation institute in comparison to the
training institute, resulting in higher intermediate SUVmean val-
ues (p < .001), despite PET protocol harmonization. Although
the external validation is not independent due to the harmo-
nized protocols, the discussed differences in image acquisition
and treatment characteristics guarantee generalizability of the
model to a certain level.Model applicability
As suggested, the developed model can be used to assist in deci-
sion making for LARC already during CRT (Fig. 1). However, three
notes have to be made. First, this model is only useful for decisions
made during or immediately after CRT, like RT boost or additional
chemotherapy. The decision for a wait-and-see approach can bet-
ter be made just before surgery by using both specialized predic-
tion models [29] and careful assessment of imaging, endoscopies
and biopsies [20]. The advantages of an earlier estimate of pCR
are avoidance of overtreatment of complete responders, a possible
increase of the number of complete responders with a RT boost for
good responders and perhaps a change in treatment strategy for
non-responding patients.
Secondly, any developed model requires prospective validation
by means of a randomized trial, comparing an arm with standard
treatment for all (CRT + surgery) to an arm receiving individualized
treatment based on the prediction model. Such a study is currently
being set up.
And last, other predictors from different sources might be con-
sidered to further improve accuracy. Diffusion-weighted magnetic
resonance imaging (DW-MRI) at different time points is reported
as a promising candidate which increases the prediction accuracy
signiﬁcantly in combination with PETCT imaging [16]. Here it is
important that also cost effectiveness studies are carried out to
ensure that the costs for making multiple PET or MRI scans are jus-
tiﬁed when compared to cost reductions due to personalizing
treatment with better outcomes and fewer complications. Blood
biomarkers also can have additional value as for example has been
reported for serum carcinoembryonic antigen (CEA) [22]. For all
these additional sources however, cost–beneﬁt analyses are
advised because saturation of the prediction accuracy can become
an issue.Conclusions
We have developed an externally validated and accurate predic-
tion model for pathologic complete response in locally advanced
rectal cancer based on large prospective studies. This nomogram
can be used to distinguish three types of patients, i.e. complete
responders, good responders and non-responders, for which
respectively a wait-and-see policy, radiotherapy boost and addi-
tional chemotherapy can be administered. This personalized treat-
ment approach is expected to promote more complete responders,
reduce the number of surgeries and related complications, and to
avoid unnecessary toxicity.Conﬂict of interest
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